People: Rigel Pharmaceuticals Inc (RIGL.O)

Summary

Name	Age	Since	Current Position
James Gower	64	2001	Chairman of the Board, Chief Executive Officer
Raul Rodriguez	52	2010	President, Chief Operating Officer
Ryan Maynard	43	2010	Chief Financial Officer, Executive Vice President
Dolly Vance	48	2010	Executive Vice President - Corporate Affairs, General Counsel, Corporate Secretary
Donald Payan	64	2008	Executive Vice President, President - Discovery and Research, Director
Elliot Grossbard	65	2008	Executive Vice President, Chief Medical Officer
Bradford Goodwin	58	2007	Independent Director
Gary Lyons	62	2005	Independent Director
Walter Moos	58	1997	Independent Director
Hollings Renton	66	2004	Independent Director
Peter Ringrose	67	2005	Independent Director
Stephen Sherwin	64	2000	Independent Director

» Insider Trading

Biographies

Name	Description
James Gower	Mr. James M. Gower is Chairman of the Board, Chief Executive Officer of Rigel Pharmaceuticals Inc. He joined the Company as President, Chief Executive Officer and as a member of Board in January 1997, and has been Company's Chairman of the Board and Chief Executive Officer since October 2001. The Board concluded that Mr. Gower should continue to serve as a member of the Board in part due to his role as company's Chief Executive Officer and his knowledge of the day-to-day operations of Rigel obtained as a result of that role. From 1992 to March 1996, Mr. Gower was President and Chief Executive Officer of Tularik Inc., a biotechnology company developing small-molecule drugs regulating gene expression. Prior to Tularik, Mr. Gower spent 10 years at Genentech, Inc., a biopharmaceutical company, where he most recently served as Senior Vice President. During his 10 years at Genentech, Mr. Gower was responsible for business development and sales and marketing functions. In addition, he established and managed Genentech's foreign operations in Canada and Japan and served as President of Genentech Development Corporation. Mr. Gower served on the board of directors of Cell Genesys, Inc., a publicly traded biotechnology company that merged with BioSante Pharmaceuticals in 2009, from 1996 until 2009. He holds a B.S. and an M.B.A. in Operations Research from the University of Tennessee.
Raul Rodriguez	Mr. Raul R. Rodriguez is President, Chief Operating Officer of Rigel Pharmaceuticals Inc., since March 2010. He joined the Company as Vice President, Business Development in April 2000, became Company's Senior Vice President, Business Development and Commercial Operations in December 2002 and became Company's Executive Vice President and Chief Operating Officer in June 2004. From 1997 to March 2000, he served as Senior Vice President, Business Development and Operations for Ontogeny, Inc., a biotechnology company. From 1994 to 1997, he served as the Executive Director, Business Development and Market Planning for Scios, Inc., a pharmaceutical company. From 1989 to 1994, Mr. Rodriguez held various positions at G.D. Searle & Company, a pharmaceutical company. In these companies, Mr. Rodriguez held positions of increasing responsibility in the areas of business development and planning. After earning his Bachelor's degree from Harvard College, Mr. Rodriguez went on to earn his Masters of Public Health at the University of Illinois and subsequently received his M.B.A. at the Stanford Graduate School of Business.
Ryan Maynard	Mr. Ryan D. Maynard is Chief Financial Officer, Executive Vice President of Rigel Pharmaceuticals Inc., since March 2010. He joined Rigel in September 2001 as Corporate Controller and was appointed as an Assistant Secretary in October 2001. In June 2006 he became Vice President of Finance and Acting Chief Financial Officer and became Vice President and Chief Financial Officer in January 2007. Prior to joining Rigel, Mr. Maynard was Corporate Controller and Director of Finance and Accounting for Personify, Inc., an e-commerce software company, from November 1999 to April 2001. From July 1998 to October 1999 he served as Controller of General Magic, Inc. and from July 1994 to June 1998 he held various positions at Siliconix, Inc., most recently as Senior Finance Manager. He previously worked at Ernst & Young, LLP, where he became a certified public accountant. Mr. Maynard holds a B.S. in Commerce—Accounting from Santa Clara University.
Dolly Vance	Ms. Dolly A. Vance is Executive Vice President - Corporate Affairs, General Counsel and Corporate Secretary of Rigel Pharmaceuticals Inc., since March 2010. Ms. Vance had been serving as Senior Vice President, General Counsel and Corporate Secretary since January 2007 and Vice President and General Counsel since January 2003. She joined Rigel in September 2000 as Rigel's first in-house counsel. Until September 2000, she was at the law firm of Flehr Hohbach Test Albritton & Herbert LLP (now Dorsey & Whitney LLP), where she was a partner. Prior to law school she worked in various research laboratories, including the laboratory of Norman Davidson at California Institute of Technology. She holds a Bachelor's degree from University of California, San Diego and a J.D. from Boston University School of Law.
Donald Payan	Dr. Donald G. Payan, M.D., is Executive Vice President, President - Discovery and Research, Director of Rigel Pharmaceuticals Inc. He is one of Company's co-founders, has been a member of Company's Board since July 1996. In February 2008, Dr. Payan became Company's Executive Vice President, President of Discovery and Research. Prior to this role, he served as Company's Executive Vice President and Chief Scientific Officer since January 1997. From January 1997 to July 1998, he also served as Company's Chief Operating Officer. From July 1996 to January 1997, Dr. Payan served as Company's President and Chief Executive Officer. The Board concluded that Dr. Payan should continue to serve as a member of the Board in part due to the fact that he brings historic knowledge and continuity to the Board as one of Company's co-founders, as well as research experience and demonstrated ability to grow new research programs. From December 1995 to May 1996, Dr. Payan was Vice President of AxyS Pharmaceuticals, Inc., a biopharmaceutical company. From September 1992 to December 1995, Dr. Payan was Executive Vice President and Chief Scientific Officer of Khepri Pharmaceuticals, Inc., a biopharmaceutical company, which he founded and subsequently merged with AxyS Pharmaceuticals. Dr. Payan did his residency training in Medicine at Massachusetts General Hospital and is a former Professor of the University of California, San Francisco and member of The Howard Hughes Medical Institute.
Elliot Grossbard	Dr. Elliott B. Grossbard, M.D., is Executive Vice President, Chief Medical Officer of Rigel Pharmaceuticals Inc., since February 2008. He has served as Company's Senior Vice President of Medical Development since April 2002. Prior to joining Rigel, Dr. Grossbard was Vice President, Clinical Affairs for Avigen Inc., an Alameda-based gene therapy products company. Before that, Dr. Grossbard served as Senior Vice President of Development and Vice President of Medical and Regulatory Affairs at Scios, Inc. He was also integral in the clinical development of Scios' lead compound Natrecor®, which was recently approved by the FDA for the treatment of acute heart failure, and the preclinical development of a variety of proteins, peptides and small molecules. From 1982 through 1990, Dr. Grossbard held the positions of Associate Director, Clinical Research, and Director, Clinical Research at Genentech Inc. At Genentech, he directed the development of the thrombolytic agent Activase® tissue plasminogen activator ("TPA") from the earliest preclinical studies through clinical trials, NDA filing and FDA approval. Dr. Grossbard joined Genentech from Hoffman-LaRoche where he held various positions in clinical research. Dr. Grossbard's primary research focus at Roche was on the interferon-alpha (Roferon®) program. Prior to joining the corporate sector, Dr. Grossbard held numerous academic appointments at such research institutions as Memorial Sloan-Kettering and Cornell University Medical Center, including Director of the Adult Bone Marrow Transplant Program at Memorial Sloan-Kettering. Dr. Grossbard serves on the board of VentiRx Pharmaceuticals, Inc., a biopharmaceutical company. Dr. Grossbard received his B.A. from Columbia College in 1969 and his M.D. from Columbia University in 1973. In addition, he received a M.S. in Law from Yale University School of Law in 1981. He trained in Medicine at Massachusetts General Hospital and in Hematology at Columbia University and Sloan-Kettering.
Bradford Goodwin	Mr. Bradford S. Goodwin is Independent Director of Rigel Pharmaceuticals Inc., since January 2007. Mr. Goodwin is currently CEO of CharlestonPharma, LLC, a biopharmaceutical company, and President and CEO of Keren Pharmaceutical, Inc., a biopharmaceutical company, and serves on the board of directors of NeurogesX. Mr. Goodwin's prior public company board service includes Chair of the board of directors of Facet Biotech Corporation from December 2008 to April 2010, when Facet was acquired by Abbot Laboratories, PDL BioPharma from 2006 to 2008, CoTherix, Inc., a biopharmaceutical company, from 2004 until 2007, when it was acquired by Actelion Pharmaceuticals Ltd., and Novacea, Inc., a publicly held biopharmaceutical company focused on in licensing, developing and commercializing novel therapies for cancer, from 2002 until 2006. From 2001 to 2006, he was Chief Executive Officer and Director of Novacea. Prior to Novacea, Mr. Goodwin was President, Chief Operating Officer and Founder of Collabra Pharma, Inc., a company focused on pharmaceutical product licensing and development. Before founding Collabra, he held various senior executive positions with Genentech, including Vice President of Finance. Mr. Goodwin holds a B.S. in Business Administration from the University of California, Berkeley.
Gary Lyons	Mr. Gary A. Lyons is Independent Director of Rigel Pharmaceuticals Inc., since October 2005. Mr. Lyons is also a member of the board of directors of Neurocrine Biosciences, Inc., a biopharmaceutical company. Mr. Lyons served as Neurocrine's Chief Executive Officer and member of its board of directors of from 1993 until 2008. Mr. Lyons also serves on the board of directors of Vical, Inc. and KaloBios Pharmaceuticals, Inc., each a biopharmaceutical company, and is Chairman of the board of directors of NeurogesX, Inc., a biopharmaceutical company. He served on the board of directors of PDL BioPharma, Inc., a biopharmaceutical company, from July 2008 until he resigned in December 2008 to join the board of directors of Facet Biotech Corporation following Facet's spin-off from PDL, and served on the board of directors until Facet's acquisition by Abbot Laboratories in April 2010. Mr. Lyons also served on the board of directors of Poniard Pharmaceuticals, a biopharmaceutical company, from June 2009 to December 2011. From 1983 to 1993, he held a number of management positions at Genentech, including Vice President of Business Development and Vice President of Sales, and also served as a member of Genentech's Executive Committee. Mr. Lyons was responsible for international licensing, acquisitions and partnering for Genentech's Corporate Venture Program and had operating responsibility for two subsidiaries, Genentech Canada, Inc. and Genentech Limited (Japan). He holds a B.S. in Marine Biology from the University of New Hampshire and an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management.
Walter Moos	Dr. Walter H. Moos, Ph.D., is Independent Director of Rigel Pharmaceuticals Inc., since March 1997. In March 2005, Dr. Moos joined SRI International, an independent nonprofit research institute, as head of the biosciences division. From 1997 to 2004, Dr. Moos served as the Chairman and Chief Executive Officer of MitoKor, Inc., a biotechnology company. Prior to that, he served as a Vice President of Chiron Corporation, a biotechnology company, and as a Vice President at the Parke-Davis Pharmaceutical Research Division of the Warner-Lambert Company. He has been an Adjunct Professor at the University of California, San Francisco, since 1992. He also has served as an adjunct faculty member at the University of Michigan and at James Madison University. Dr. Moos served on the board of directors of MIGENIX Inc., a biopharmaceutical company, from 2004 to 2008. He has also served on the boards of numerous private companies and several non-profit organizations. Dr. Moos has been an advisor to the National Academy of Sciences and venture capital firms. Dr. Moos holds an A.B. from Harvard University and a Ph.D. in Chemistry from the University of California, Berkeley.
Hollings Renton	Mr. Hollings C. Renton is Independent Director of Rigel Pharmaceuticals Inc., since January 2004. From June 2000 to March 2008, Mr. Renton served as Chairman of the Board of Onyx Pharmaceuticals, Inc., a publicly held biopharmaceutical company, where he also served as President and Chief Executive Officer from March 1993 and a director from April 1992. Prior to joining Onyx, Mr. Renton was the President and Chief Operating Officer of Chiron Corporation, a multinational biotechnology company. He assumed that position in 1991 on Chiron's acquisition of Cetus Corporation, a biotechnology company, where he had been President since 1990 and Chief Operating Officer since 1987. He joined Cetus in 1981 and was Chief Financial Officer from 1983 to 1987. He holds an M.B.A. from the University of Michigan and a B.S. in Mathematics from Colorado State University. Mr. Renton serves as Chairman of the board of directors of Affymax, Inc., a publicly held biopharmaceutical company, as Co-Chairman of the board of directors and lead director of Portola Pharmaceuticals, Inc., a biopharmaceutical company, and as a member of the board of directors of Cepheid.
Peter Ringrose	Dr. Peter S. Ringrose, Ph.D., is Independent Director of Rigel Pharmaceuticals Inc., since February 2005. Dr. Ringrose's experience in the pharmaceutical industry spans more than 40 years and includes key leadership positions as Senior Vice President for Worldwide Drug Discovery and Medicinal R & D Europe at Pfizer Inc., a pharmaceutical company, and Division Director of Chemotherapy, Infectious Diseases and Molecular Sciences at the Sandoz Research Institute in Vienna, Austria. In 2002, Dr. Ringrose retired from Bristol-Myers Squibb, a pharmaceutical company, where he served as Chief Scientific Officer from January 2000 to December 2002, as well as President of the Pharmaceutical Research Institute from January 1997 to December 2002. Dr. Ringrose has served as chair of the Biotechnology and Biological Sciences Research Council (UK) from 2003 until 2009, and was a member of the UK Government's Technology Strategy Board. He is a Council member of the Foundation for Science and Technology in the United Kingdom and also chairs the Corporate Partnership Board at Pembroke College, Cambridge where he is a lifetime Honorary Pitt Fellow. Dr. Ringrose is also a non-executive director of Theravance Inc. and Biotica Technology Ltd. (Cambridge UK), each of which is a biopharmaceutical company, was a director of Astex Therapeutics, Inc., a biopharmaceutical company, until September 2011, when it was acquired, and served on the Scientific Advisory Boards of Schering-Plough Research Institute, Cempra Pharmaceuticals, Inc. and Accenture Inc. Dr. Ringrose also served on the board of governors for the New York Academy of Sciences from 1999 to 2005. He has served on the boards of Cambridge Antibody Technology Ltd., ImClone Systems, Inc. and Pfizer, Ltd. and on the Scientific Advisory Board at Merlin Biosciences Ltd. Dr. Ringrose received a B.S., an M.A. and a Ph.D. from the University of Cambridge.
Stephen Sherwin	Dr. Stephen A. Sherwin, M.D., is Independent Director of Rigel Pharmaceuticals Inc., since March 2000. Dr. Sherwin is Chairman of Ceregene, Inc., a company that he co-founded in 2001 which develops gene therapies for neurodegenerative diseases. Dr. Sherwin was elected to the board of directors of Verastem, Inc. in March of 2013, and also serves on the boards of directors of BioSante Pharmaceuticals, Neurocrine Biosciences and Biogen Idec, each of which is a biotechnology company. In addition, Dr. Sherwin has served on the board of the Biotechnology Industry Organization since 2002 and is currently its Chairman Emeritus. Until Cell Genesys merged with BioSante Pharmaceuticals in 2009, Dr. Sherwin served as Chief Executive Officer of Cell Genesys from the beginning of the Cell Genesys' operations in 1990, and also served as Chairman of its board of directors from 1994. He was also co-founder and Chairman of the board of directors of Abgenix, Inc, an antibody company that was acquired by Amgen, Inc. in 2006. From 1983 to 1990, Dr. Sherwin held various positions at Genentech, most recently as Vice President of Clinical Research. Prior to 1983, he was on the staff of the National Cancer Institute. Dr. Sherwin holds a B.A. summa cum laude in Biology from Yale University and an M.D. from Harvard Medical School. He is board-certified in internal medicine and medical oncology and is currently a Clinical Professor of Medicine at University of California, San Francisco and an Attending Physician in the Hematology/Oncology Division at San Francisco General Hospital. He is a fellow of the American College of Physicians and a member of the American Society of Clinical Oncology.

Basic Compensation

Name	Fiscal Year Total
James Gower	2,300,270
Raul Rodriguez	1,665,830
Ryan Maynard	1,456,880
Dolly Vance	389,869
Donald Payan	1,905,440
Elliot Grossbard	1,575,250
Bradford Goodwin	--
Gary Lyons	--
Walter Moos	--
Hollings Renton	--
Peter Ringrose	--
Stephen Sherwin	--

As Of 30 Dec 2012

Options Compensation

Name	Options	Value
James Gower	665,000	659,700
Raul Rodriguez	336,389	16,500
Ryan Maynard	76,700	180,709
Dolly Vance	295,000	168,706
Donald Payan	414,251	69,508
Elliot Grossbard	310,000	16,500
Bradford Goodwin	0	0
Gary Lyons	0	0
Walter Moos	0	0
Hollings Renton	0	0
Peter Ringrose	0	0
Stephen Sherwin	0	0

Insider Trading

Name	Shares Traded	Price
VANCE DOLLY A	4,151	$10.43
MAYNARD RYAN D	23,302	$6.49
MAYNARD RYAN D	23,302	$10.67
MAYNARD RYAN D	17,586	$10.52
MAYNARD RYAN D	17,586	$6.49
MAYNARD RYAN D	34,112	$10.55
MAYNARD RYAN D	34,112	$6.49
MAYNARD RYAN D	1,700	$6.49
MAYNARD RYAN D	600	$10.62
MAYNARD RYAN D	700	$10.60
MAYNARD RYAN D	300	$10.63
MAYNARD RYAN D	100	$10.61
PAYAN DONALD G	100	$8.71
PAYAN DONALD G	9,700	$8.70
PAYAN DONALD G	100	$8.72
PAYAN DONALD G	100	$8.75
FLYNN JAMES E	229,252	$8.00
FLYNN JAMES E	301,424	$8.00
FLYNN JAMES E	46,524	$8.00
FLYNN JAMES E	72,800	$8.00

» Full list on Insider Trading

People: Rigel Pharmaceuticals Inc (RIGL.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: